Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Ruxolitinib Resistance or Intolerance in Steroid-Refractory Chronic Graft-Versus-Host Disease - a Real-World Single Center Analysis

Gulrayz Ahmed, Amer Al Homssi, Ramsha Ahmed, Walter Longo, Nirav N. Shah, Lyndsey Runaas, Marcelo C. Pasquini, Timothy S. Fenske, Lisa E Rein, Aniko Szabo, Mehdi Hamadani, Sameem Abedin

Blood (2024) 144 (Supplement 1): 7346.

https://doi.org/10.1182/blood-2024-209225

Published: 2024

Journal Articles

Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis

Blood (2024) 144 (Supplement 1): 1042.

https://doi.org/10.1182/blood-2024-193827

Published: 2024

Journal Articles

Early Safety and Feasibility Results from a Phase II Trial of De-Escalated Ptcy and Ruxolitinib for Gvhd Prophylaxis in Older Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT

Sameem Abedin, Fateeha Furqan, Lyndsey Runaas, Walter Longo, Nirav N. Shah, Timothy S. Fenske, Marcelo C. Pasquini, William R Drobyski, Xue-Zhong Yu, Mehdi Hamadani

Blood (2024) 144 (Supplement 1): 1039.

https://doi.org/10.1182/blood-2024-200832

Published: 2024

Journal Articles

Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

Blood (2024) 144 (Supplement 1): 221.

https://doi.org/10.1182/blood-2024-201595

Published: 2024

Journal Articles

A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Yesid Alvarado-Valero, Rachel J. Cook, Shira N. Dinner, Michael Keng, Kebede Begna, Sameem Abedin, MHD Monzr M. Al Malki, Vijaya Raj Bhatt, Nathalie Javidi-Sharifi, Prabhu Rajagopolan, Sandra Wiley, Richard G Ghalie, Matthew S. Davids

Blood (2024) 144 (Supplement 1): 2878.

https://doi.org/10.1182/blood-2024-198718

Published: 2024

Journal Articles

Outcome of Patients with TP53 Mutated Relapsed/Refractory AML with Lintuzumab-Ac225 in Combination with CLAG-M Following Venetoclax Plus Hypomethylating Agent Therapy

Sameem Abedin, Guru Subramanian Guru Murthy, Mehdi Hamadani, Laura C. Michaelis, Karen-Sue Carlson, Lyndsey Runaas, Katelyn Gauger, Avinash Desai, Mary Chen, Patrik Brodin, Kate L Li, Mojisola Rotibi, Umar Sayeed, Alexandra M. Harrington, Ehab L. Atallah

Blood (2024) 144 (Supplement 1): 4258.

https://doi.org/10.1182/blood-2024-201559

Published: 2024

Journal Articles

A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A Myelomatch Treatment Trial: ECOG-ACRIN MM20A-EA02

Jessica Kaplan Altman, Zhuoxin Sun, Alexander E. Perl, Richard Little, Steven D. Gore, Laura C. Michaelis, Geoffrey L. Uy, Yasmin Abaza, Sameem Abedin, John L. Reagan, Ehab L. Atallah, Selina Luger, Mark R. Litzow

Blood (2024) 144 (Supplement 1): 2907.1.

https://doi.org/10.1182/blood-2024-199701

Published: 2024

Journal Articles

OPTIMIZE: A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide As GVHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Jeffery J. Auletta, Steven M. Devine, Heather E. Stefanski, Stephen R. Spellman, Todd E. Defor, Brent R. Logan, Brandan J. Butler, Mahasweta Gooptu, Brian C. Shaffer, Antonio M. Jimenez Jimenez, Sameem Abedin, Dipenkumar Modi, MHD Monzr M. Al Malki, Rachel J. Cook

Blood (2024) 144 (Supplement 1): 3514.1.

https://doi.org/10.1182/blood-2024-198252

Published: 2024

Journal Articles

CNS Status at Diagnosis Can Identify Acute Myeloid Leukemia Patients with Poor Induction Outcomes

Kristine Broge-Reynen, Emily Giever, Aniko Szabo, Ryan Conrardy, Nicole M Held, Laura C. Michaelis, Lyndsey Runaas, Sameem Abedin, Guru Subramanian Guru Murthy, Karen-Sue Carlson, Ravi Kishore Narra, Sumana Devata, Sheila Swartz, Valarie Ehrlich, Mary Rodgers, Allison Johnson, Ehab L. Atallah

Blood (2024) 144 (Supplement 1): 5173.

https://doi.org/10.1182/blood-2024-208834

Published: 2024

Journal Articles

Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations

Blood (2024) 144 (Supplement 1): 212.

https://doi.org/10.1182/blood-2024-207106

Published: 2024

Journal Articles

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Blood (2023) 142 (Supplement 1): 2159.

https://doi.org/10.1182/blood-2023-187433

Published: 2023

Journal Articles

A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL) or Acute Myeloid Leukemia (AML)

Matthew S Davids, Yesid Alvarado Valero, Catherine Diefenbach, Daniel N. Egan, Shira N. Dinner, Monzr M. Al Malki, Kebede Begna, Avyakta Kallam, Sameem Abedin, Rachel Cook, Nathalie Javidi-Sharifi, Edward Dominguez, Lu Miao, Richard G Ghalie, Alexey Danilov

Blood (2023) 142 (Supplement 1): 4286.

https://doi.org/10.1182/blood-2023-179577

Published: 2023

Journal Articles

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations

Blood (2023) 142 (Supplement 1): 57.

https://doi.org/10.1182/blood-2023-172422

Published: 2023

Journal Articles

Comparative Analysis of Clinical Outcomes and Healthcare Resource Utilization (HRU) in Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Unfit for High-Intensity Chemotherapy Treated with Venetoclax (VEN) Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative

Blood (2023) 142 (Supplement 1): 5173.

https://doi.org/10.1182/blood-2023-173283

Published: 2023

Journal Articles

Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study

Blood (2023) 142 (Supplement 1): 222.

https://doi.org/10.1182/blood-2023-179454

Published: 2023

Journal Articles

Infectious and Non-Infectious Pulmonary Complications in HCT Patients Treated with Post Transplant Cyclophosphamide (PTCy) Based Gvhd Prophylaxis

Skyler Taylor, Annie Kim, Paul Cho, Kinaya Smith, Mehdi Hamadani, Sameem Abedin

Blood (2023) 142 (Supplement 1): 6990.

https://doi.org/10.1182/blood-2023-184702

Published: 2023

Journal Articles

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Blood (2023) 142 (Supplement 1): 3529.

https://doi.org/10.1182/blood-2023-189040

Published: 2023

Journal Articles

Maintenance Ruxolitinib Is Associated with Low Rates of Chronic Gvhd Requiring Systemic Treatment in Older Adults with AML/MDS Undergoing Allogeneic HCT: Results of a Phase II Multicenter Trial

Zachariah Defilipp, Haesook T. Kim, Laura Knight, Suzanne O'Connor, Meghan White, Bhagirathbhai Dholaria, Mark A. Schroeder, Sumithira Vasu, Sameem Abedin, Areej El-Jawahri, Steven McAfee, Yi-Bin Chen, Gabriela S. Hobbs

Blood (2023) 142 (Supplement 1): 653.

https://doi.org/10.1182/blood-2023-180423

Published: 2023

Journal Articles

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

Blood (2023) 142 (Supplement 1): 469.

https://doi.org/10.1182/blood-2023-182177

Published: 2023

Journal Articles

Standardized Communication Tool Improves Inpatient-Outpatient Care Transitions for Adults with Acute Leukemia

Blood (2022) 140 (Supplement 1): 5083–5085.

https://doi.org/10.1182/blood-2022-159809

Published: 2022

NARROW

Ruxolitinib Resistance or Intolerance in Steroid-Refractory Chronic Graft-Versus-Host Disease - a Real-World Single Center Analysis

Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis

Early Safety and Feasibility Results from a Phase II Trial of De-Escalated Ptcy and Ruxolitinib for Gvhd Prophylaxis in Older Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT

Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Outcome of Patients with TP53 Mutated Relapsed/Refractory AML with Lintuzumab-Ac225 in Combination with CLAG-M Following Venetoclax Plus Hypomethylating Agent Therapy

A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A Myelomatch Treatment Trial: ECOG-ACRIN MM20A-EA02

OPTIMIZE: A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide As GVHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

CNS Status at Diagnosis Can Identify Acute Myeloid Leukemia Patients with Poor Induction Outcomes

Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL) or Acute Myeloid Leukemia (AML)

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations

Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study

Infectious and Non-Infectious Pulmonary Complications in HCT Patients Treated with Post Transplant Cyclophosphamide (PTCy) Based Gvhd Prophylaxis

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Maintenance Ruxolitinib Is Associated with Low Rates of Chronic Gvhd Requiring Systemic Treatment in Older Adults with AML/MDS Undergoing Allogeneic HCT: Results of a Phase II Multicenter Trial

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

Standardized Communication Tool Improves Inpatient-Outpatient Care Transitions for Adults with Acute Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only